SCHEMBL20437154

SCHEMBL20437154

COC(=O)[C@@H](Cc1ccc(Oc2ccnc3c2ccn3S(=O)(=O)c2ccc(C)cc2)cc1)NC(=O)OC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.44
POLB P06746 1/20 0.44
KMT2A Q03164 1/20 0.44
BCL2 P10415 6/20 0.41
P2RX7 Q99572 2/20 0.40
ITGB3 P05106 1/20 0.37
ITGA2B P08514 1/20 0.37
ABCB1 P08183 1/20 0.37
MMP13 P45452 1/20 0.37
KLK5 Q9Y337 1/20 0.37
KLK7 P49862 1/20 0.36
ATM Q13315 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
ALOX5 P09917 1/20 0.36
CYP3A4 P08684 1/20 0.36
SCN9A Q15858 1/20 0.36
MCL1 Q07820 1/20 0.36
YAP1 P46937 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20422562 1.00 MEN1 (0.44) MEN1POLBKMT2ABCL2P2RX7
SCHEMBL20437157 0.93 MEN1 (0.49) MEN1POLBKMT2ABCL2P2RX7
SCHEMBL21626648 0.89 MEN1 (0.43) MEN1POLBKMT2ABCL2KLK5
SCHEMBL20437214 0.89 MEN1 (0.43) MEN1POLBKMT2ABCL2P2RX7
SCHEMBL20439497 0.89 MEN1 (0.43) MEN1POLBKMT2ABCL2P2RX7
SCHEMBL20806019 0.88 MEN1 (0.37) MEN1POLBKMT2ABCL2P2RX7
SCHEMBL20437152 0.87 BCL2 (0.40) MEN1POLBKMT2ABCL2P2RX7
SCHEMBL20437150 0.87 BCL2 (0.40) MEN1POLBKMT2ABCL2P2RX7
SCHEMBL20437194 0.86 SCN9A (0.40) BCL2ITGB3ITGA2BKLK5ATM
SCHEMBL21593115 0.86 MEN1 (0.40) MEN1POLBKMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10954236-B2 Tyrosine amide derivatives as Rho-Kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2021-03-23 US disclosed
EP-3573987-B1 TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARM SPA (IT) 2021-03-10 EP disclosed
US-20180215758-A1 TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2018-08-02 US disclosed
US-20180215758-A1 TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2018-08-02 US disclosed
WO-2018138293-A1 TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2018-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10954236-B2 Tyrosine amide derivatives as Rho-Kinase inhibitors ROCK1, ROCK2, CIT MEN1 4596/4885POLB 2905/4885KMT2A 1361/4885
US-20180215758-A1 TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS ROCK1, ROCK2, CIT MEN1 4596/4885POLB 2905/4885KMT2A 1361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.